PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 17, 2026Current Reviews in Clinical and Experimental Pharmacology

Mechanistic Insights and Therapeutic Potential of MCC950 as a NLRP3Inflammasome Inhibitor in Multiple Sclerosis: A Narrative Review

View Full Paper
Ask AI
Bookmark
Share

Authors

FRFatemeh RabieiHAHamid AskariAVArshia Vala

Discussion

Loading...

Member takes

Overview

Narrative review evaluates MCC950's potential in reducing neuroinflammation in multiple sclerosis, suggesting new therapeutic avenues.

Key Points

  • This review aims to explore the mechanistic insights and therapeutic potential of MCC950 as an NLRP3 inflammasome inhibitor in multiple sclerosis.
  • Comprehensive literature search conducted in PubMed, Scopus, and Web of Science.
  • Focus on studies related to NLRP3 inflammasome and MCC950 in multiple sclerosis.
  • Evaluation of in vivo and preclinical studies up to 2025.
  • MCC950 suppresses NLRP3–ASC–caspase-1 oligomerization and reduces IL-1β/IL-18 release.
  • Treatment preserves oligodendrocyte integrity and mitigates axonal loss and microglial/astrocytic activation.
  • Delivery systems like PEGylated nanoparticles enhance MCC950's bioavailability.

Cite This Study

Rabiei et al. (2026) studied this question.

synapsesocial.com/papers/6a095bef7880e6d24efe1d4dhttps://doi.org/10.2174/0127724328444835260407154423
View Full Paper
Ask AI
Bookmark
Share